Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,648,379

« Back to Dashboard
Patent 5,648,379 protects RELENZA and is included in one NDA.

This patent has sixty-two patent family members in thirty-six countries.

Summary for Patent: 5,648,379

Title: Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents
Abstract:Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid, pharmaceutical formulations thereof, methods for their preparation and their use in the treatment of viral infections, in particular influenza, are described.
Inventor(s): Von Itzstein; Laurence Mark (North Fitzroy, AU), Wu; Wen-Yang (Mount Waverley, AU), Van Phan; Tho (Carnegie, AU), Danylec; Basil (Box Hill, AU), Jin; Betty (Mount Waverly, AU), Colman; Peter Malcolm (East Melbourne, AU), Varghese; Joseph Noozhumurry (Brunswick, AU)
Assignee: Biota Scientific Management Pty., Ltd. (Melbourne, AU)
Application Number:08/325,074
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use;
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999RXYes5,648,379<disabled>PROPHYLAXIS OF INFLUENZA
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999RXYes5,648,379<disabled>TREATMENT OF INFLUENZA
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999RXYes5,648,379<disabled>ZANAMIVIR FOR INHALATION
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,648,379

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPJ 9800Apr 24, 1990
AustraliaPK 2896Oct 19, 1990
AustraliaPK 4537Feb 11, 1991

Non-Orange Book Patents for Patent: 5,648,379

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,360,817 Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,648,379

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong1003834Nov 06, 1998
China1057260Dec 25, 1991
Norway974670Oct 09, 1997
Canada2291994Oct 14, 2003
European Patent Office0526543Apr 21, 1993990030Netherlands<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc